TaiGen and TTY Biopharm Jointly Develop and Commercialize a Novel Topoisomerase I Inhibitor DB67 for Cancer Treatment
21-Oct-2003 -
TAIPEI, Taiwan - TaiGen Biotechnology Co., Ltd. and TTY Biopharm Co., Ltd. announced the signing of an agreement to jointly develop and market a novel topoisomerase I inhibitor, DB67, for cancer treatment.
DB67, the lead compound of a series of topoisomerase I inhibitors, was discovered and ...
biotechnology
clinical trials
drug development
+6